Tango Therapeutics, Inc. 8-K

What Happened Tango Therapeutics, Inc. announced the results of its virtual 2026 annual meeting held June 4, 2026. Stockholders elected two Class II directors — Malte Peters, M.D., and Mace Rothenberg, M.D. — ratified PricewaterhouseCoopers LLP as the company’s independent auditor for FY2026, and approved the non‑binding advisory vote on named executive officer compensation (say‑on‑pay). The record date was April 7, 2026; 144,242,271 shares were outstanding and 131,198,081 shares (90.96%) were present or represented by proxy, establishing a quorum. Kanishka Pothula had resigned effective May 13, 2026 and was not re‑elected; his resignation was not due to any disagreement with the company.

Key Details

• Meeting date and format: June 4, 2026, virtual-only webcast; quorum: 131,198,081 shares (90.96% of 144,242,271 outstanding).
• Director election vote totals:
  • Malte Peters, M.D.: For 98,188,796; Withheld 17,623,596; Broker non‑votes 15,385,689.
  • Mace Rothenberg, M.D.: For 92,476,172; Withheld 23,336,220; Broker non‑votes 15,385,689.
• Auditor ratification: PwC ratified — For 131,097,992; Against 73,823; Abstain 26,266.
• Say‑on‑pay (advisory): Approved — For 113,915,877; Against 1,855,838; Abstain 40,677; Broker non‑votes 15,385,689.

Why It Matters These outcomes confirm the company’s board composition and governance choices for investors: two director seats were filled, the company’s auditor for FY2026 was approved, and shareholders expressed advisory support for executive compensation. The vote totals and broker non‑votes show the level of shareholder participation and support for each proposal; the say‑on‑pay is advisory (non‑binding) but indicates investor sentiment on management pay. No other matters were voted on at the meeting.